Skip to main content

Research Repository

Advanced Search

Dual pathway inhibition in atherothrombosis prevention: yes, now we can!

SUMMARIA, Francesco; BIONDI-ZOCCAI, Giuseppe; ROMAGNOLI, Enrico; MAMAS, Mamas A.; FRANCHI, Francesco; SEVERINO, Paolo; LAVALLE, Carlo; VERSACI, Francesco; GASPARDONE, Achille; BHATT, Deepak L.

Authors

Francesco SUMMARIA

Giuseppe BIONDI-ZOCCAI

Enrico ROMAGNOLI

Francesco FRANCHI

Paolo SEVERINO

Carlo LAVALLE

Francesco VERSACI

Achille GASPARDONE

Deepak L. BHATT



Abstract

Despite ongoing developments, prevention and treatment of atherothrombotic cardiovascular disease remains a common challenge. Antithrombotic options for cardiocerebrovascular disease prevention involves a choice between dual antiplatelet therapy (DAPT) and dual pathway inhibition (DPI), which includes an antiplatelet agent and a reduced dose anticoagulant agent. In selected patients at high risk of event and low risk of bleeding, especially those undergoing recent and complex coronary revascularization using drug-eluting stents (DES) ("revascularization-driven effect"), DAPT is superior to single antiplatelet therapy with aspirin. DPI involves a wider potential range of treatment and is superior to single antiplatelet therapy with aspirin, particularly in patients with atherothrombotic involvement in different vascular beds both previously revascularized and not ("no revascularization-driven effect"). After nearly thirty years of randomized trials and observational registries, we have sufficient data to customize antithrombotic therapy in patients at high cardiovascular risk. Therefore, "atherothrombosis stakeholders" must identify the right patient for the right therapy to ensure high levels of efficacy and safety with the best of current therapeutic opportunities.

Citation

SUMMARIA, F., BIONDI-ZOCCAI, G., ROMAGNOLI, E., MAMAS, M. A., FRANCHI, F., SEVERINO, P., …BHATT, D. L. (2023). Dual pathway inhibition in atherothrombosis prevention: yes, now we can!. Minerva Cardiology and Angiology, 71(4), 363-373. https://doi.org/10.23736/S2724-5683.21.05867-1

Journal Article Type Review
Acceptance Date Nov 11, 2021
Online Publication Date Nov 11, 2021
Publication Date 2023-08
Journal Minerva Cardiol Angiol
Print ISSN 2724-5683
Publisher Edizioni Minerva Medica
Peer Reviewed Peer Reviewed
Volume 71
Issue 4
Pages 363-373
DOI https://doi.org/10.23736/S2724-5683.21.05867-1
Public URL https://keele-repository.worktribe.com/output/426747
Publisher URL https://www.minervamedica.it/en/journals/minerva-cardiology-angiology/article.php?cod=R05Y9999N00A21111102